AlphAIAlphAI — Financial news for AI agents
investing.comOCT 302 min read$SYK

Citizens cuts Stryker stock price target to $390 on weak quarter

Citizens cut Stryker's (SYK) price target to $390 from $400, citing weak Q3 results. Stryker missed revenue ($6.52B vs. $6.62B) and EPS ($3.52 vs. $3.55) estimates, lowering full-year guidance. Despite challenges, InvestingPro notes the stock is undervalued at $312.

Original reporting
investing.com
Published Oct 30, 2026, 10:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 10:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$SYK
Bearish
high confidence
Mentioned
$SYK
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SYKBearishMed
01

Why it matters

The earnings miss and guidance reduction are likely to drive short‑term downside, but the company's cash generation and repurchase program provide a floor.

02

Market read

First‑report earnings and guidance update for a large‑cap medical‑tech company, creating actionable trading considerations.

03

What to watch

Cyber‑attack and SAP implementation issues are temporary; underlying cash flow remains solid.

Relevance 8/10Novelty 8/10Timing: today

Background

Stryker reported Q3 2026 results that fell short of consensus, prompting analysts to lower price targets and guidance.

Company-level read

Ticker impact

$SYKBearishHigh confidence
Context

Citizens lowered its price target to $390 and Stryker cut full-year revenue and EPS guidance after reporting Q3 results that missed estimates.

Expected impact

likely pressure as the market prices in the lower guidance and reduced price target

Evidence & confidence

Earnings miss combined with reduced guidance and analyst target typically trigger sell‑offs in the short term.

Market effects

Sector

Medical technology sector may see broader valuation pressure as Stryker's guidance miss highlights demand headwinds.

Regional

U.S. equities, especially healthcare equipment stocks, could be affected.

Global

Limited to U.S. markets; no immediate global ripple.

Counterpoint

What could challenge this read

The strong product pipeline and a new $3 billion share repurchase program could support the stock if execution improves.

Key entities

  • Analyst
    Citizens

    Lowered price target to $390 and maintained Market Outperform rating.

  • Analyst
    Needham

    Reduced price target to $359, citing slower growth.

Read at source← All news

StoryStryker cuts FY 2026 outlook after Q3 miss and operational setbacks

Also covered by

4 outlets

Related articles

OCT 30
$SYKHighAI 8/10

Piper Sandler cuts Stryker stock price target on Q3 miss

Piper Sandler reduced its price target for Stryker (NYSE:SYK) to $325 from $390 after Q3 results missed expectations. The company lowered its full-year guidance, citing deceleration in the large joint market. Shares are down 24% from their 52-week high. Multiple analysts have adjusted their targets and ratings following the earnings report.

investing.com2 min
OCT 30
$SYKMedAI 8/10

Stryker (SYK) Q3 2026 Earnings Call Transcript

Stryker (SYK) reported Q3 2026 earnings, with organic sales growth of 7.7% and adjusted EPS of $3.52. The company faced delays in new product sales due to a cyber incident and SAP implementation but remains confident in long-term growth. Stryker updated its guidance, expecting similar Q4 growth. Recent acquisitions include ZuriMED and an investment in CMR Surgical. Vascular business showed sequential improvement, and the company anticipates commercializing AVS' IVL platform in 2027.

finance.yahoo.com8 min
OCT 30
$SYKHighAI 9/10

Stryker lowers 2026 guidance after slowdown in hip, knee procedures

Stryker reported Q3 revenue of $6.5B, up 7.7% YoY, but net earnings fell 12.3% YoY. CEO Kevin Lobo cited a market slowdown in hip and knee procedures due to economic challenges. The company lowered its 2026 sales guidance to 6.5-7.0% from 8.3-9.3%. Lobo will step down as CEO at year-end, succeeded by COO Spencer Stiles. Stryker also invested $400M in CMR Surgical for U.S. distribution rights.

finance.yahoo.com2 min